- 2023.09.26
As a global innovative biotech company, we are passionate about creating transformational therapies through innovation to address unmet medical needs in oncology for patients worldwide.
Lemzoparlimab CD47
Uliledlimab CD73
Givastomig Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB
mRNA, Probody
AI Design, Alphabody
Press Releases
2023.09.05
I-Mab announced participation in investor conferences in September 2023.
2023.08.17
The Company today announced its financial results for the 6 months ended June 30, 2023, and provided key business updates.
2023.08.08
I-Mab will host an investor call to report interim earnings on Aug 17.